Thumbnail Image
Publication

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).

Andronis, L
; 
Goranitis, I
; 
Pirrie, S
; 
Pope, A
; 
Barton, D
; 
Collins, S
; 
Daunton, A
; 
McLaren, D
; 
O'Sullivan, J
; 
Parker, C
... show 10 more
Citations
Altmetric:
Abstract
To evaluate the cost-effectiveness of adding zoledronic acid or strontium-89 to standard docetaxel chemotherapy for patients with castrate-refractory prostate cancer (CRPC).
Authors
Andronis, L
Goranitis, I
Pirrie, S
Pope, A
Barton, D
Collins, S
Daunton, A
McLaren, D
O'Sullivan, J
Parker, C
Porfiri, E
Staffurth, J
Stanley, A
Wylie, James P
Beesley, S
Birtle, A
Brown, J
Chakraborti, P
Hussain, S
Russell, J
Billingham, L
James, N
Affiliation
Health Economics Unit, University of Birmingham, UK
Description
Date
2016-06-03
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
Open access full text article
Adobe PDF, 200.6 KB
Keywords
Type
Article
Citation
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). 2016: BJU Int
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/618169
Embedded videos